hallitus tiedottaa,
vaikka tiedemiehet varoittavat asiasta,
The Guardian
Brittiläisen
Addaction mukaan luokituksen nostamisella ei ole olennaista merkitystä.
Transform Drug Policy Foundation epäilee myös luokituksen noston järkevyyttä,
täällä
Timesonline
"A report from the advisory council concluded that the health dangers
from cannabis did not justify its inclusion in the higher category
and that it should remain a Class C drug. Professor Sir Michael
Rawlins, chairman of the council, said: "Changing the classification
of cannabis is neither warranted nor will it achieve the desired effect."
The report said that scientific evidence pointed to a "probable, but
weak, causal link between psychotic illness, including schizophrenia,
and cannabis use". However, it added that in the population as a
whole, the drug played only a "modest role" in the development of
these conditions."